BACKGROUND: Optimization of COVID-19 vaccination rate among healthcare personnel is of utmost priority to secure provision of uninterrupted care and to protect the most vulnerable patients. This study, as part of the global CoVaST project, aimed to assess the occurrence of short-term adverse events (SRAEs) of two most administered COVID-19 vaccines, mRNA-based (Pfizer-BioNTech and Moderna) and viral vector-based (AstraZeneca) in healthcare sector workers (HWs). METHODS: A cross-sectional survey-based study was carried out for the first time among 317 Polish healthcare sector personnel and medical students using a validated and pre-tested questionnaire. The online questionnaire included 25 pre-tested, validated questions concerning demographic data, medical parameters, COVID-19-related anamneses, and local or systemic reactions (reactogenicity) associated with COVID-19 vaccination. Descriptive statistics, inferential tests and binary logistic regression were performed. RESULTS: Out of the 247 participating HWs, 79.8% were females, and 77.5% received mRNA-based vaccines, while 24.5% received a viral vector-based vaccine. Cumulatively, 78.9% and 60.7% of the participants reported at least one local and one systemic SRAE respectively, following their COVID-19 first or second dose of vaccine. A wide array of SRAEs was observed, while pain at injection site (76.9%) was the most common local SRAE, and fatigue (46.2%), headache (37.7%), muscle pain (31.6%) were the most common systemic SRAEs. The vast proportion of local (35.2%) and systemic (44.8%) SRAEs subsided up to 1 day after inoculation with both types of vaccines. The mRNA-based vaccine versions seem to cause higher prevalence of local SRAEs, mainly pain within injection site (81.3% vs. 71.7%; p = 0.435), while the viral vector-based vaccine was linked with increased incidents of mild systemic side effects (76.7% vs. 55.3%; p = 0.004) after both doses. Pooled analysis revealed uniform results while comparing the prevalence of SRAEs in HWs as recipients in four central European countries (OR = 2.38; 95% CI = 2.03-2.79). CONCLUSIONS: The study confirmed the safety of commonly administered vaccines against COVID-19, which were associated with mild, self-resolving adverse events. No major vaccine-related incidents were reported which would affect every day functioning, significantly. The younger age group (below 29 y.o.) were associated with an increased risk of adverse events generally. The results enhanced current data regarding COVID-19 vaccination active surveillance in selected occupational groups.

Czech National Centre for Evidence Based Healthcare and Knowledge Translation Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Kamenice 5 625 00 Brno Czech Republic

Department of Oral and Maxillofacial Surgery Justus Liebig University Klinikstrasse 33 35392 Giessen Germany

Department of Public Health Faculty of Medicine Masaryk University Kamenice 5 625 00 Brno Czech Republic

Department of Restorative Dentistry with Endodontics Medical University of Silesia 40 055 Katowice Poland

Zobrazit více v PubMed

Khunti K., Kamal A., Pareek M., Griffiths A. Should vaccination for healthcare workers be mandatory? J. R. Soc. Med. 2021;114:235–236. doi: 10.1177/01410768211013525. PubMed DOI PMC

World Health Organization Strategic Advisory Group of Experts on Immunization. WHO SAGE Roadmap for Prioritizing uses of COVID-19 Vaccines in the Context of Limited Supply. November 2020. [(accessed on 30 October 2021)]. Available online: https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines-in-the-context-of-limited-supply.

Johnson S.B., Butcher F. Doctors during the COVID-19 pandemic: What are their duties and what is owed to them? J. Med. Ethics. 2021;47:12–15. doi: 10.1136/medethics-2020-106266. PubMed DOI PMC

Bar-On Y.M., Goldberg Y., Mandel M., Bodenheimer O., Freedman L., Kalkstein N., Mizrahi B., Alroy-Preis S., Ash N., Milo R., et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N. Engl. J. Med. 2021;385:1393. doi: 10.1056/NEJMoa2114255. PubMed DOI PMC

World Health Organisation Poland. [(accessed on 10 September 2021)]. Available online: https://covid19.who.int/region/euro/country/pl.

European Medicines Agency (EMA) EMA Recommends First COVID-19 Vaccine for Authorisation in the EU. [(accessed on 15 September 2021)]. Available online: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu.

European Medicines Agency (EMA) Comirnaty. [(accessed on 15 August 2021)]. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/21fizer21ty.

European Medicines Agency (EMA) EMA Recommends COVID-19 Vaccine Moderna for Authorisation in the EU. [(accessed on 15 August 2021)]. Available online: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu.

European Medicines Agency (EMA) EMA Recommends COVID-19 Vaccine AstraZeneca for Authorisation in the EU. [(accessed on 15 August 2021)]. Available online: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu.

COVID-19 Vaccine Tracker. [(accessed on 20 September 2021)]. Available online: https://covid19.trackvaccines.org/country/21fizer.

Serwis Rzeczypospolitej Polskiej The Report of Vaccination against COVID-19. [(accessed on 15 September 2021)]; Available online: https://www.gov.pl/web/szczepimysie/raport-szczepien-przeciwko-covid-19.

Serwis Rzeczypospolitej Polskiej The National Vaccination Program. [(accessed on 15 September 2021)]; Available online: https://www.gov.pl/web/szczepimysie/narodowy-program-szczepien-przeciw-covid-19.

Nour S., Plourde G. Pharmacoepidemiology and Pharmacovigilance: Synergistic Tools to Better Investigate Drug Safety. Academic Press; Cambridge, MA, USA: 2018. pp. 1–224.

Medicines & Healthcare Products Regulatory Agency (MHRA) Medicines and Healthcare Products Regulatory Agency (MHRA) Report of the Commission on Human Medicines Expert Working Group on COVID-19 Vaccine Safety Surveillance. [(accessed on 12 September 2021)]; Available online: https://www.gov.uk/government/publications/report-of-the-commission-on-human-medicines-expert-working-group-on-covid-19-vaccine-safety-surveillance/report-of-the-commission-on-human-medicines-expert-working-group-on-covid-19-vaccine-safety-surveillance.

Serwis Rzeczypospolitej Polskiej The Adverse Post-Vaccination Events (Poland) [(accessed on 12 September 2021)]; Available online: https://www.gov.pl/web/szczepimysie/niepozadane-odczyny-poszczepienne.

Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Berry S., Canas L.S., Graham M.S., Klaser K., Modat M., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: A prospective, community-based, nested, case-control study. Lancet Infect. Dis. 2021 doi: 10.1016/S1473-3099(21)00460-6. PubMed DOI PMC

Riad A., Pokorná A., Attia S., Klugarová J., Koščík M., Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J. Clin. Med. 2021;10:1428. doi: 10.3390/jcm10071428. PubMed DOI PMC

Jęśkowiak I., Wiatrak B., Grosman-Dziewiszek P., Szeląg A. The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19. Vaccines. 2021;9:502. doi: 10.3390/vaccines9050502. PubMed DOI PMC

Riad A., Hocková B., Kantorová L., Slávik R., Spurná L., Stebel A., Havriľak M., Klugar M. Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia. Pharmaceuticals. 2021;14:873. doi: 10.3390/ph14090873. PubMed DOI PMC

Menni C., Klaser K., May A., Polidori L., Capdevila J., Louca P., Sudre C.H., Nguyen L.H., Drew D.A., Merino J., et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet. Infect. Dis. 2021;21:939–949. doi: 10.1016/S1473-3099(21)00224-3. PubMed DOI PMC

Kadali R.A.K., Janagama R., Peruru S., Gajula V., Madathala R.R., Chennaiahgari N., Malayala S.V. Adverse effects of COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J. Med. Virol. 2021;93:4420–4429. doi: 10.1002/jmv.26996. PubMed DOI PMC

Kadali R.A.K., Janagama R., Peruru S., Malayala S.V. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int. J. Infect. Dis. 2021;106:376–381. doi: 10.1016/j.ijid.2021.04.047. PubMed DOI PMC

Almufty H.B., Mohammed S.A., Abdullah A.M., Merza M.A. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab. Syndr. Clin. Res. Rev. 2021;15:102207. doi: 10.1016/j.dsx.2021.102207. PubMed DOI PMC

Vita E.D., Sbrana F., Quattrone F., Pino B.D., Megaro M., Lombardi R., Prontera C., Passino C., Petrillo M. Adverse events and humoral response after two doses of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) mRNA vaccine in the hospital personnel of a cardiopulmonary tertiary-care center. Infect. Control. Hosp. Epidemiol. 2021:1–3. doi: 10.1017/ice.2021.321. PubMed DOI PMC

Abu-Hammad O., Alduraidi H., Abu-Hammad S., Alnazzawi A., Babkair H., Abu-Hammad A., Nourwali I., Qasem F., Dar-Odeh N. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. Vaccines. 2021;9:577. doi: 10.3390/vaccines9060577. PubMed DOI PMC

Cuschieri S., Borg M., Agius S., Souness J., Brincat A., Grech V. Adverse reactions to Pfizer-BioNTech vaccination of healthcare workers at Malta’s state hospital. Int. J. Clin. Pract. 2021;75:e14605. doi: 10.1111/ijcp.14605. PubMed DOI PMC

El-Shitany N.A., Harakeh S., Badr-Eldin S.M., Bagher A.M., Eid B.G., Almukadi H.S., Alghamdi B.S., Alahmadi A.A., Hassan N.A., Sindi N., et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine among Saudi Residents: A Retrospective Cross-Sectional Study. Int. J. Gen. Med. 2021;14:1389–1401. doi: 10.2147/IJGM.S310497. PubMed DOI PMC

Klugar M., Riad A., Mekhemar M., Conrad J., Buchbender M., Howaldt H.-P., Attia S. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology. 2021;10:752. doi: 10.3390/biology10080752. PubMed DOI PMC

Centres for Diseases Control and Prevention (CDC) Reactions and Adverse Events of the Pfizer-BioNTech COVID-19 Vaccine. [(accessed on 17 September 2021)]; Available online: https://www.cdc.gov/vaccines/covid-19/info-by-product/fizer/reactogenicity.html.

Babicki M., Mastalerz-Migas A. Attitudes toward Vaccination against COVID-19 in Poland. A Longitudinal Study Performed before and Two Months after the Commencement of the Population Vaccination Programme in Poland. Vaccines. 2021;13:503. doi: 10.3390/vaccines9050503. PubMed DOI PMC

Bauernfeind S., Hitzenbichler F., Huppertz G., Zeman F., Koller M., Schmidt B., Plentz A., Bauswein M., Mohr A., Salzberger B. Brief report: Attitudes towards Covid-19 vaccination among hospital employees in a tertiary care university hospital in Germany in December 2020. Infection. 2021;1:1–5. doi: 10.1007/s15010-021-01622-9. PubMed DOI PMC

Szmyd B., Karuga F.F., Bartoszek A., Staniecka K., Siwecka N., Bartoszek A., Błaszczyk M., Radek M. Attitude and Behaviors towards SARS-CoV-2 Vaccination among Healthcare Workers: A Cross-Sectional Study from Poland. Vaccines. 2021;9:218. doi: 10.3390/vaccines9030218. PubMed DOI PMC

Edwards B., Biddle N., Gray M., Sollis K. COVID-19 vaccine hesitancy and resistance: Correlates in a nationally representative longitudinal survey of the Australian population. PLoS ONE. 2021;16:e0248892. doi: 10.1371/journal.pone.0248892. PubMed DOI PMC

Salali G.D., Uysal M.S. COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey. Psychol. Med. 2020;19:1–3. doi: 10.1017/S0033291720004067. PubMed DOI PMC

Aw J., Seng J.J.B., Seah S.S.Y., Low L.L. COVID-19 Vaccine Hesitancy-A Scoping Review of Literature in High-Income Countries. Vaccines. 2021;13:900. doi: 10.3390/vaccines9080900. PubMed DOI PMC

Momentive Inc SurveyMonkey: The World’s Most Popular Free Online Survey Tool. [(accessed on 15 July 2021)]. Available online: https://www.surveymonkey.com.

Klugar M., Riad A. COVID-19 Vaccines Safety Tracking (CoVaST). ClinicalTrials.gov. [(accessed on 15 July 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04834869.

Portal Gov.pl Pytania i Odpowiedzi. Szczepienie Przeciwko COVID-19. [(accessed on 15 July 2021)]; Available online: https://www.gov.pl/web/szczepimysie/pytania-i-odpowiedzi.

Riad A., Schünemann H., Attia S., Peričić T.P., Žuljević M.F., Jürisson M., Kalda R., Lang K., Morankar S., Yesuf E.A., et al. COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines’ Side Effects. Int. J. Environ. Res. Public Health. 2021;18:7859. doi: 10.3390/ijerph18157859. PubMed DOI PMC

Riad A., Pokorná A., Mekhemar M., Conrad J., Klugarová J., Koščík M., Klugar M., Attia S. Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States. Vaccines. 2021;9:673. doi: 10.3390/vaccines9060673. PubMed DOI PMC

Riad A., Sağıroğlu D., Üstün B., Pokorná A., Klugarová J., Attia S., Klugar M. Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey. J. Clin. Med. 2021;10:2629. doi: 10.3390/jcm10122629. PubMed DOI PMC

Centres for Diseases Control and Prevention (CDC) Pfizer-BioNTech COVID-19 Vaccine Overview and Safety (Also Known as COMIRNATY) [(accessed on 14 November 2020)]; Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html.

Centres for Diseases Control and Prevention (CDC) Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine. [(accessed on 2 April 2021)]; Available online: https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html.

European Medicines Agency (EMA) COVID-19 Vaccine AstraZeneca. [(accessed on 15 July 2021)]. Available online: https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf.

World Health Organization (WHO) Process of Translation and Adaptation of Instruments. [(accessed on 25 December 2020)]. Available online: https://www.who.int/substance_abuse/research_tools/translation/en/

WMA World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA J. Am. Med. Assoc. 2013;310:2191–2194. doi: 10.1001/jama.2013.281053. PubMed DOI

Von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. UroToday Int. J. 2009;2 doi: 10.1097/EDE.0b013e3181577654. PubMed DOI

Proton Technologies AG General Data Protection Regulation (GDPR) Compliance Guidelines. HORIZON 2020—Project REP-791727-1. [(accessed on 1 May 2021)]. Available online: https://gdpr.eu/

Mathioudakis A.G., Ghrew M., Ustianowski A., Ahmad S., Borrow R., Papavasileiou L.P., Petrakis D., Bakerly N.D. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life. 2021;17:249. doi: 10.3390/life11030249. PubMed DOI PMC

Li X., Ostropolets A., Makadia R., Shoaibi A., Rao G., Sena A.G., Martinez-Hernandez E., Delmestri A., Verhamme K., Rijnbeek P.R., et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: Multinational network cohort study. BMJ. 2021;373:n1435. doi: 10.1136/bmj.n1435. PubMed DOI PMC

Alhazmi A., Alamer E., Daws D., Hakami M., Darraj M., Abdelwahab S., Maghfuri A., Algaissi A. Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines. 2021;18:674. doi: 10.3390/vaccines9060674. PubMed DOI PMC

Resta C.D., Ferrari D., Viganò M., Moro M., Sabetta E., Minerva M., Ambrosio A., Locatelli M., Tomaiuolo R. The Gender Impact Assessment among Healthcare Workers in the SARS-CoV-2 Vaccination—An Analysis of Serological Response and Side Effects. Vaccines. 2021;9:522. doi: 10.3390/vaccines9050522. PubMed DOI PMC

Luxi N., Giovanazzi A., Capuano A., Crisafulli S., Cutroneo P.M., Fantini M.P., Ferrajolo C., Moretti U., Poluzzi E., Raschi E., et al. Ilmiovaccino COVID19 collaborating group. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug. Saf. 2021;5:1–23. PubMed PMC

Negahdaripour M., Shafiekhani M., Moezzi S.M., Amiri S., Rasekh S., Bagheri A., Mosaddeghi P., Vazin A. Administration of COVID-19 vaccines in immunocompromised patients. Int. Immunopharmacol. 2021;99:108021. doi: 10.1016/j.intimp.2021.108021. PubMed DOI PMC

Jeyanathan M., Afkhami S., Smaill F., Miller M.S., Lichty B.D., Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 2020;20:615–632. doi: 10.1038/s41577-020-00434-6. PubMed DOI PMC

Bettini E., Locci M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines. 2021;9:147. doi: 10.3390/vaccines9020147. PubMed DOI PMC

Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. PubMed DOI PMC

Bartsch S.M., O’Shea K.J., Wedlock P.T., Strych U., Fergusons M.C., Bottazzi M.E., Randall S.L., Siegmund S.S., Cox S.N., Hotez P.J., et al. The Benefits of Vaccinating with the First Available COVID-19 Coronavirus Vaccine. Am. J. Prev. Med. 2021;60:605–613. doi: 10.1016/j.amepre.2021.01.001. PubMed DOI PMC

Zdziarski K., Landowski M., Zabielska P., Karakiewicz B. Subjective Feelings of Polish Doctors after Receiving the COVID-19 Vaccine. Int. J. Environ. Res. Public Health. 2021;10:6291. doi: 10.3390/ijerph18126291. PubMed DOI PMC

Freeman D., Loe B.S., Chadwick A., Vaccari C., Waite F., Rosebrock L., Jenner L., Petit A., Lewandowsky S., Vanderslott S., et al. COVID-19 vaccine hesitancy in the UK: The Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychol. Med. 2020:1–15. doi: 10.1017/S0033291720005188. PubMed DOI PMC

Pataka A., Kotoulas S., Stefanidou E., Grigoriou I., Tzinas A., Tsiouprou I., Zarogoulidis P., Courcoutsakis N., Argyropoulou P. Acceptability of Healthcare Professionals to Get Vaccinated against COVID-19 Two Weeks before Initiation of National Vaccination. Medicina. 2021;57:611. doi: 10.3390/medicina57060611. PubMed DOI PMC

Bergwerk M., Gonen T., Lustig Y., Amit S., Lipsitch M., Cohen C., Mandelboim M., Levin E.G., Rubin C., Indenbaum V., et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N. Engl. J. Med. 2021;28:NEJMoa2109072. doi: 10.1056/NEJMoa2109072. PubMed DOI PMC

Li M., Luo Y., Watson R., Zheng Y., Ren J., Tang J., Chen Y. Healthcare workers’ (HCWs) attitudes and related factors towards COVID-19 vaccination: A rapid systematic review. Postgrad. Med. J. 2021;30 doi: 10.1136/postgradmedj-2021-140195. PubMed DOI

Di Gennaro F., Murri R., Segala F.V., Cerruti L., Abdulle A., Saracino A., Bavaro D.F., Fantoni M. Attitudes towards Anti-SARS-CoV2 Vaccination among Healthcare Workers: Results from a National Survey in Italy. Viruses. 2021;26:371. doi: 10.3390/v13030371. PubMed DOI PMC

Kateeb E., Danadneh M., Pokorná A., Klugarová J., Abdulqader H., Klugar M., Riad A. Predictors of Willingness to Receive COVID-19 Vaccine: Cross-Sectional Study of Palestinian Dental Students. Vaccines. 2021;9:954. doi: 10.3390/vaccines9090954. PubMed DOI PMC

Riad A., Huang Y., Abdulqader H., Morgado M., Domnori S., Koščík M., Mendes J.J., Klugar M., Kateeb E., IADS-SCORE Universal Predictors of Dental Students’ Attitudes towards COVID-19 Vaccination: Machine Learning-Based Approach. Vaccines. 2021;9:1158. doi: 10.3390/vaccines9101158. PubMed DOI PMC

Adams S.H., Schaub J.P., Nagata J.M., Park M.J., Brindis C.D., Irwin C.E., Jr. Young Adult Perspectives on COVID-19 Vaccinations. J. Adolesc. Health. 2021;69:511–514. doi: 10.1016/j.jadohealth.2021.06.003. PubMed DOI PMC

Riad A., Abdulqader H., Morgado M., Domnori S., Koščík M., Mendes J.J., Klugar M., Kateeb E., on behalf of IADS-SCORE Global Prevalence and Drivers of Dental Students’ COVID-19 Vaccine Hesitancy. Vaccines. 2021;9:566. doi: 10.3390/vaccines9060566. PubMed DOI PMC

Baumeister A., Chakraverty D., Aldin A., Seven Ü.S., Skoetz N., Kalbe E., Woopen C. “The system has to be health literate, too”—Perspectives among healthcare professionals on health literacy in transcultural treatment settings. BMC Health Serv. Res. 2021;21:716. doi: 10.1186/s12913-021-06614-x. PubMed DOI PMC

Lo Re V., Klungel O.H., Chan K.A., Panozzo C.A., Zhou W., Winterstein A.G. Global covid-19 vaccine rollout and safety surveillance—How to keep pace. BMJ. 2021;373:1416. doi: 10.1136/bmj.n1416. PubMed DOI

Side Effects of COVID-19 Vaccines Primer Doses: Experience of Saudi Healthcare Workers Participating in CoVaST-SA

COVID-19 vaccine booster hesitancy (VBH) of healthcare professionals and students in Poland: Cross-sectional survey-based study

Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers

Prevalence and Drivers of COVID-19 Vaccine Booster Hesitancy Among German University Students and Employees

COVID-19 Vaccine Acceptance of Pregnant and Lactating Women (PLW) in Czechia: An Analytical Cross-Sectional Study

COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study

The Impact of Information Sources on COVID-19-Related Knowledge, Attitudes, and Practices (KAP) among University Students: A Nationwide Cross-Sectional Study